ISPE has hired John Bournas as President and CEO, succeeding Nancy Berg who announced plans to leave the Society last fall. Mr. Bournas takes the helm at ISPE with extensive competencies in the healthcare association industry as well as significant international experience.
Fitch Ratings expects that revenues from biologic therapies as a percentage of total pharmaceutical sales will continue to increase over the intermediate term as companies increase their prominence in their drug portfolios, according to a report published today.
Neurotrope Initiates Phase 2a Study of Bryostatin for the Treatment of Alzheimer's Disease - Doses First PatientsJuly 29, 2014 9:13 am | News | Comments
Neurotrope announced today that it has initiated a Phase 2a clinical trial to evaluate bryostatin for the treatment of patients with Alzheimer's disease (AD). Bryostatin is a potent modulator of the enzyme protein kinase C epsilon (PKCe).
With some 100 million people infected with forms of hepatitis, China is the world’s epicenter for the illness.
Getting relief from a slowdown in health care spending, the program's giant hospital trust fund won't be exhausted until 2030, the government said Monday. That's four years later than last year's estimate.
U.S. health officials are monitoring the Ebola outbreak in Africa but say the risk of the deadly germ spreading to the United States is remote.
Idaho prison officials say they had to have thousands of dollars' worth of medications shipped overnight to the state's largest prison after the former operator, Corrections Corporation of America, left the facility without a promised eight-day supply of inmate drugs.
European Commission Approves Eliquis for the Treatment of Deep Vein Thrombosis and Pulmonary EmbolismJuly 29, 2014 8:38 am | News | Comments
Bristol-Myers Squibb and Pfizer announced that the European Commission has approved Eliquis for the treatment of DVT and PE, and the prevention of recurrent DVT and PE in adults. The European Commission approval applies to all European Union (EU) member states as well as Iceland and Norway.
Pfizer's second-quarter earnings plunged 79 percent from last year, when the world's second-largest drugmaker booked a business spinoff gain of more than $10 billion, but results in the most recent quarter still edged analyst expectations.
In less than six months, prescriptions for Sovaldi have eclipsed all other hepatitis C pills combined, according to new data from IMS Health. But clinical and commercial successes have triggered scrutiny for the drug's manufacturer, California-based Gilead Sciences Inc., which just reported second-quarter profits of $3.66B.
The Corning, New York-based company said earnings fell to $169 million, or 11 cents per share, from $638 million, or 43 cents per share, in the same quarter a year ago.
Impax Laboratories announced that the FDA performed a general GMP inspection and a Pre-Approval Inspection for RYTARY at the company's Taiwan manufacturing facility from July 21 to July 26, 2014. At the conclusion of the inspection, the FDA issued a Form 483 with ten inspectional observations.
Merck has reported earnings that more than doubled in its second quarter, and topped analysts' expectations. The Whitehouse Station, New Jersey-based company said net income increased to $2 billion, or 68 cents per share, from $906 million, or 30 cents per share, in the same quarter a year earlier.
A Shanghai court says American and British investigators who worked for drug maker GlaxoSmithKline will stand trial Aug. 8 on charges of illegally obtaining information on Chinese citizens. The Shanghai No. 1 Intermediate People's Court said Tuesday that Yingzeng Yu and her husband Peter Humphrey will have a "public trial."
Pharmacyclics, Inc. announced that the FDA has granted IMBRUVICA regular (full) approval for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy, and for the treatment of CLL patients with deletion of the short arm of chromosome 17 (del 17p CLL), including treatment naive and previously treated del 17p CLL patients.